| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 334.98 | 11.0% | 44.3% |
| Total Income | 334.98 | 11.0% | 44.3% |
| Expenditure | 464.10 | 9.7% | 37.1% |
| PBT | -119.96 | 7.4% | 20.1% |
| Net Profit | -120.14 | 7.2% | 20.3% |
| OPM | -38.55% | 1.68pp | 7.31pp |
| NPM | -35.87% | 1.29pp | 7.18pp |
| EPS | -0.90 | 5.9% | 12.5% |
Guardant Health Reports Q2 2026 Financial Results and Raises 2026 Revenue Guidance
31 Jul 2026 · 31 Jul, 1:44 am
Summary
Guardant Health announced strong second quarter 2026 financial results, with total revenue increasing 44% year-over-year to $335.0 million, driven by robust performance in Oncology and Screening segments. The company raised its full-year 2026 revenue guidance to $1.34 to $1.36 billion, reflecting expected growth of 36% to 38%. Despite a net loss of $120.1 million for the quarter, management expressed optimism about broad-based momentum and strategic milestones, including FDA approvals and expanded coverage for its tests.
Key Highlights
- 1
Guardant Health reported total revenue of $335.0 million for the second quarter of 2026, an increase of 44% year-over-year.
- 2
Oncology revenue grew 38% to $219.1 million, driven by a 63% increase in test volume.
- 3
Screening revenue saw significant growth, increasing over 250% to $52.9 million with Shield test volume reaching approximately 66,000.
- 4
Non-GAAP gross margin improved to 67% in the second quarter of 2026, up from 66% in the prior year period.
- 5
The company raised its full-year 2026 revenue guidance to a range of $1.34 to $1.36 billion, representing 36% to 38% growth.
- 6
Net loss for the second quarter of 2026 was $120.1 million, or $0.90 per share, compared to a net loss of $99.9 million, or $0.80 per share, in the prior year period.
Management Comments
Helmy Eltoukhy
Our second-quarter performance reflected broad-based momentum across the Guardant portfolio, with revenue increasing 44% year over year. Growth was fueled by strong oncology volume, with acceleration across every product. The landmark FDA approval of Guardant360 Liquid CDx further strengthens our portfolio and positions us to drive sustained growth in the years ahead.
AmirAli Talasaz
Our team delivered another quarter of exceptional growth for Shield, and we are excited about several important milestones that reinforce its expanding role in colorectal cancer screening. The inclusion of the Shield blood test in the American Cancer Society’s screening guidelines, together with UnitedHealth Group’s broad coverage decision, represents powerful validation of Shield’s clinical utility and its potential to improve access to screening.
Informational and educational content only. Not investment advice.